Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Avenzo Therapeutics Announces Clinical Study Collaboration With Gilead Sciences To Evaluate AVZO-021 And Trodelvy In HR+/HER2- Metastatic Breast Cancer

Author: Benzinga Newsdesk | September 03, 2024 09:03am

AVZO-021, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Trodelvy (sacituzumab govitecan-hziy), Gilead's Trop-2 directed ADC

Combination therapy to be evaluated as part of the ongoing Phase 1/2 study in patients with HR+/HER2- metastatic breast cancer

Avenzo will sponsor the clinical trial and Gilead will provide Trodelvy

Avenzo plans to initiate combination cohorts with AVZO-021 in fourth quarter of 2024

Posted In: GILD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist